Iovance Biotherapeutics enters September with a striking reversal in its short book — the same bears that were quietly retreating two weeks ago have snapped back hard, and the options market has shifted its tone to match.
The short interest story has changed materially since the last note. Short interest climbed 16.8% on the week to 25.8% of the free float — roughly 102.5 million shares — reversing a decline that had been running for most of August. That is a significant rebuild. The previous note flagged shorts edging down to 22.3% of float on August 24; they have added more than three percentage points since. The ORTEX short score reflects this, climbing to 72.4 and ranking in just the 9th percentile on short score — meaning the bearish signal is more elevated than 91% of the universe. Days to cover runs at 4.8 on the latest FINRA fortnightly data, a figure that gives any squeeze meaningful time to develop.
The borrow market tells a different story from the short interest headline. Availability is relatively comfortable at 138% — meaning there are roughly 1.4 shares available to lend for every share currently borrowed — and that reading has actually loosened over the past week from around 128%. Cost to borrow has also eased, dropping 15% on the week to 0.45%. That combination — short interest surging while borrow loosens and borrowing costs fall — suggests the new shorts entered with capacity on their side. The lending market is not under stress. Availability spent late July and early August tighter, near 70–90%, and the current ease is a meaningful contrast. Bears can add without fighting for inventory.
Options positioning has stepped back from the extreme reading that led the previous article, but remains cautious by recent standards. The put/call ratio is at 0.46, above its 20-day mean of 0.39 and roughly 1.3 standard deviations elevated — not the three-sigma alarm of August 21's 0.49 print, but still running hotter than the 0.28–0.36 band that dominated through most of July. The 52-week high on the PCR remains 0.49, set just over a week ago. The options market has moderated its defensive stance rather than abandoned it.
The Street is broadly constructive, and recent analyst activity tilted upward following the August earnings print. TD Cowen raised its target to $10 from $7 on August 25, maintaining a Buy. Mizuho lifted to $11 from $10 on August 18. Barclays went to $13 from $11 on August 7. Even UBS, sitting at Neutral, moved its target to $7 from $4. The consensus mean price target sits at $10, implying about 21% upside from the current $8.28 close — though UBS at Neutral represents the bear camp view that the re-rating has already captured much of the near-term Amtagvi commercial progress. The stock itself has done the heavy lifting: up 103% on the month, with the doubling largely driven by the August 6 earnings catalyst that produced a 46% single-day gain and a 50% five-day move.
That earnings reaction is the key context for everything happening now. Institutional flows show BlackRock adding 5.9 million shares through July, and State Street building 7.0 million shares, both crossing the 5% filing threshold — passive index demand tracking a stock that had been rising. But the short rebuild happening simultaneously suggests a cohort of investors viewing the post-earnings level as stretched. The price-to-book multiple has moved from roughly 3.2 to 5.1 over the past 30 days, and EV/EBITDA is deeply negative at -28x, reflecting a company still burning cash on its Amtagvi commercial ramp and manufacturing scale-up.
Correlated peers had a rough week. FHTX fell 16.9% and WHWK dropped 8.9%, while PRQR lost 10.9% — broad-based weakness across the small-cap biotech cohort that IOVA managed to largely sidestep, closing down only 1.9% on the week. That relative resilience, against a backdrop of heavy short rebuilding, is the tension worth watching. The next earnings event is flagged for November 6 — a long enough runway that positioning ahead of it is still early, but the speed of the short rebuild in a single week suggests the market is already repricing conviction on both sides.
See the live data behind this article on ORTEX.
Open IOVA on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
